When the role of β-ARs in diminished contractility in HF was first elucidated, the initial hypothesis was to increase inotropy through stimulation of cardiac β-ARs via agonists such as Epi, NEpi, and dobutamine as a clinical treatment for HF. This evidence concerns the gene CTBP1 and hydrops fetalis.